Releases Details
Director Dealings and Issue of Equity
Released : July 16, 2020 18:04
MaxCyte, Inc.
("MaxCyte" or the "Company")
Director Dealings and Issue of Equity
Following the Exercise and Sale, Mr Doerfler's holding of Common Stock remains unchanged at a total of 433,197 Common Stock and Mr Holtz's holding of Common Stock remains unchanged at a total of 150,251 Common Stock, representing 0.57% and 0.20%, respectively, of the enlarged issued share capital of the Company and following the Exercise, Mr. Doerfler and Mr. Holtz hold a further 2,813,480 and 1,239,892 options over Common Stock.
Total voting rights
Application will be made for admission of the 575,000 New Common Stock to trading on AIM, which is anticipated to occur at 8:00am on 23 July 2020 ("Admission"). The New Common Stock will rank pari passu with the existing shares of common stock of the Company and will trade in the unrestricted line of Common Stock trading under the symbol MXCT. The total issued stock capital of the Company following the above will be 77,160,006 shares of common stock. Shareholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the stock capital of the Company.
The number of unrestricted shares of Common Stock trading under the symbol 'MXCT' is 67,259,917 and the number of restricted shares of Common Stock trading under the symbol 'MXCL' is 9,900,089.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||
|
a) |
Name |
Doug Doerfler |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
Chief Executive Officer |
|
|
b) |
Initial notification/Amendment |
Initial notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
MaxCyte, Inc. |
|
|
b) |
LEI |
54930053YHXULRFCU991 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument |
Exercise of options and Sale of Common Stock |
|
|
b) |
Identification Code |
US57777K1060 |
|
|
c) |
Nature of the transaction |
Exercise of options and Sale of Common Stock by PDMR |
|
|
d) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
N/A
|
400,000 (option exercise) 400,000 (sale of common stock) |
||
|
e) |
Aggregated information - Aggregated volume - Price |
N/A N/A N/A |
|
|
f) |
Date of the transaction |
16 July 2020 |
|
|
g) |
Place of the transaction |
London Stock Exchange, AIM Market (XLON) |
|
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||
|
a) |
Name |
Ron Holtz |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
Chief Financial Officer |
|
|
b) |
Initial notification/Amendment |
Initial notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
MaxCyte, Inc. |
|
|
b) |
LEI |
54930053YHXULRFCU991 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument |
Exercise of options and Sale of Common Stock |
|
|
b) |
Identification Code |
US57777K1060 |
|
|
c) |
Nature of the transaction |
Exercise of options and Sale of Common Stock by PDMR |
|
|
d) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
N/A
|
175,000 (option exercise) 175,000 (sale of common stock) |
||
|
e) |
Aggregated information - Aggregated volume - Price |
N/A N/A N/A |
|
|
f) |
Date of the transaction |
16 July 2020 |
|
|
g) |
Place of the transaction |
London Stock Exchange, AIM Market (XLON) |
|
About MaxCyte
MaxCyte is a clinical-stage global cell-based therapies and life sciences company. As the inventors of the premier cell-engineering enabling technology, the Company helps bring the promise of next-generation cell and gene-editing therapies to life. The Company's technology is currently being deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licences have been granted for more than 120 cell therapy programmes, with more than 90 licensed for clinical use, and the Company has now entered into eleven clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998, is listed on the London Stock Exchange (AIM:MXCT, MXCL) and is headquartered in
For further information, please contact:
|
|
|
||||||||
|
|
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the
